Skip to Main Content

Paper Details

A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With <i>Bacillus anthracis</i>.
Front Microbiol
1
2022
Mice, PamCSK, Raxibacumab, TLR, TLR1, TLR2, Toll-Like Receptor 2, Toll-like receptor, anthrax, ciprofloxacin, doxycycline, infectious diseases, mice, mouse, obiltoxaximab
Author NameAffiliation
Chih-Yuan ChiangUnited States Army Medical Research Institute of Infectious Diseases
Sina BavariUnited States Army Medical Research Institute of Infectious Diseases
Rekha G PanchalUnited States Army Medical Research Institute of Infectious Diseases
  • 1 - 3

Datasets

Release 1.2